论文部分内容阅读
多年来二甲双胍以其安全性高、价格低及疗效好的优点而广泛应用于临床治疗糖尿病。糖尿病增加了肝癌的罹患率并影响其预后。近年来研究发现二甲双胍在治疗Ⅱ型糖尿病(T2MD)患者时亦降低了其罹患肝癌的风险,大量研究证明其具有抗癌及协同抗癌作用。现本文对二甲双胍在Ⅱ型糖尿病患者中对肝癌发生的影响进行探讨,对二甲双胍抑制肿瘤的分子生物学机制进行了介绍,列举了最新的实验研究数据,并对现有临床数据进行分析,对于二甲双胍未来的研究方向提出了预期,对于二甲双胍未来在Ⅱ型糖尿病患者中肝癌的预防作用进行了简要的总结及未来使用的展望,对于其在Ⅱ型糖尿病合并肝癌的患者中的治疗作用进行了前瞻性的探讨,为二甲双胍在其他癌症防治中的应用提出了可能性。
For many years, metformin has been widely used in clinical treatment of diabetes because of its high safety, low price and good curative effect. Diabetes increases the incidence of liver cancer and affects its prognosis. In recent years, studies have found that metformin in patients with type 2 diabetes (T2MD) also reduces the risk of liver cancer, a large number of studies have shown that it has anti-cancer and synergistic anti-cancer effect. This article discusses the impact of metformin in the development of hepatocellular carcinoma in patients with type 2 diabetes mellitus on the molecular mechanism of metformin tumor suppression were introduced, the latest experimental data are listed, and the existing clinical data analysis, for metformin Future directions for the study put forward expectations that the future of Metformin in the prevention of liver cancer in patients with type 2 diabetes in the brief summary and future prospects for the treatment of type 2 diabetes patients with hepatocellular carcinoma in the treatment of prospective Of the discussion for the prevention and treatment of metformin in other cancer proposed the possibility.